dolutegravir
AssetAlso DTG, GSK 1349572, GSK1349572A, S-349572
HIV integrase strand transfer inhibitor preventing viral DNA integration into host genome.
- Stage
- Approved
- Modality
- Small molecule
- Target
- Not known
- 9
- Indications
- 136
- Trials
- 1
- Developer
Indications
9HIV infection
Approved, ema.europa.eu, 7 Oct 2026
HIV-1 infection
Approved, accessdata.fda.gov, 7 Oct 2026
Immunodeficiency
Approved, ema.europa.eu, 7 Oct 2026
6 more
In the full profile
- Owner and partners1
- Trials136
- Evidence for its targets1
- Competitors4
Every asset’s record: target, stage, trials and the evidence behind it.